Veliparib News and Research

RSS

Adding veliparib to chemotherapy can extend progression-free survival in patients with “BRCA-like” breast cancer

Results from the SWOG S1416 clinical trial show that adding veliparib to chemotherapy can significantly extend progression-free survival (PFS) times in patients with triple-negative breast cancer (TNBC) that has a "BRCA-like" phenotype.

31 Jan 2023

Research reveals new treatment avenue for pediatric high grade gliomas harboring a genetic mutation

Researchers at the University of Michigan Rogel Cancer Center have identified a novel treatment approach to an aggressive type of pediatric brain cancer, using therapies already approved to treat cancer.

16 Nov 2022

Researchers take a cue from viruses to make glioblastoma more vulnerable to treatment

In the tough war against glioblastoma, scientists are taking a cue from viruses on how to make the aggressive cancer more vulnerable to treatment.

1 Nov 2022

SWOG scientists to deliver online presentations at ASCO20 Virtual Scientific Program

Researchers from SWOG, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, will make 31 presentations as part of the ASCO20 Virtual Scientific Program, the online annual meeting of the American Society of Clinical Oncology (ASCO), which runs May 29-31.

19 May 2020

PARP inhibitor drugs can be structurally modified to better kill tumor cells

A prospective "PARP inhibitor" drug that has struggled to show effectiveness in clinical trials against cancers can be structurally modified to greatly increase its power to kill tumor cells, researchers from Penn Medicine report this week in Science.

12 Apr 2020

Intensive new combination therapy for ovarian cancer shows promising results

Researchers have found that more intensive chemotherapy maintenance for ovarian cancer could be beneficial for patients. The results of the study were presented at the ESMO Congress 2019 in Barcelona, Spain last weekend on the 28th of September.

30 Sep 2019

PARP inhibitor combined with chemotherapy increases survival for newly diagnosed ovarian cancer patients

Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that initial treatment with the PARP inhibitor veliparib in combination with chemotherapy significantly increased progression-free survival for patients with newly diagnosed, metastatic high-grade serous ovarian cancer, according to the results of the VELIA trial.

28 Sep 2019

Two genomic tests help identify most effective treatment for breast cancer patients

New results from a long-running trial to identify which new drugs or combinations of drugs are most effective in which types of breast cancer, show that two genomic tests are bringing the era of truly personalized medicine ever nearer.

14 Nov 2018

I-SPY2 research initiative employs exciting new model for testing breast cancer drugs

In a new paradigm of breast cancer research, physicians are fast-tracking promising new experimental drugs for further study, while immediately dropping drugs and drug combinations that don't work.

8 Jul 2016

Certain ARID1a mutations sensitize some tumors to PARP inhibitor drugs

Mutations in ARID1a, which are common in many cancer types, disrupt DNA damage repair in cancer cells, allowing the cancer to progress. This gene may also be an Achilles' heel when treating certain tumors, according to a team of researchers at The University of Texas MD Anderson Cancer Center.

12 Jun 2015

Phase 2 results from Abbvie’s veliparib study in NSCLC presented at ASCO 2015

AbbVie, a global biopharmaceutical company, today announced findings from a Phase 2 study of the investigational medicine veliparib combined with the chemotherapy regimen carboplatin and paclitaxel that showed an improvement in median progression-free survival (PFS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC) who are current smokers.

2 Jun 2015

AbbVie and Myriad Genetics expand Tumor BRACAnalysis CDx collaboration

Myriad Genetics, Inc. announced today that it has signed an expanded companion diagnostic agreement with AbbVie, Inc., a leading global biopharmaceutical company to use Tumor BRACAnalysis CDx™ as a companion diagnostic in support of AbbVie’s novel poly (ADP-ribose) polymerase or PARP inhibitor, veliparib.

4 Nov 2014

Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

AbbVie released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with chemotherapy, which showed a 35 percent improvement (P-value=0.14) in progression-free survival (PFS) and a 30 percent improvement (P-value=0.21) in overall survival (OS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC).

30 Sep 2014

Cedars-Sinai investigators developing novel treatment for locally advanced pancreatic cancer

Investigators at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute are developing a novel, multistep investigational treatment for one of the most complex and difficult-to-treat forms of the disease, locally advanced pancreatic cancer.

23 Jul 2014

Oral cancer drug improves outcomes in women with resistant gynecologic cancers

An oral cancer drug improves outcomes while minimizing side effects in women with gynecologic cancers who carry a BRCA mutation and whose disease is not responding to other therapies, suggests preliminary research.

26 Mar 2014

Synta Pharmaceuticals' Hsp90 inhibitor ganetespib selected for study in I-SPY 2 TRIAL

Synta Pharmaceuticals Corp. and QuantumLeap Healthcare Collaborative today announced that Synta's lead drug candidate, the Hsp90 inhibitor ganetespib, has been selected for study in the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2).

11 Mar 2014

AbbVie's global sales reduce 1.8% to $5.111B in fourth quarter 2013

AbbVie today announced financial results for the fourth quarter and full year ended Dec. 31, 2013.

31 Jan 2014

FNIH Biomarkers Consortium announces initial results of I-SPY 2 trial for breast cancer

The I-SPY 2 TRIAL, a randomized phase II clinical trial for breast cancer launched through a unique partnership with the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium and sponsored by QuantumLeap Healthcare Collaborative has graduated the first two drugs from its innovative, multidrug standing platform trial.

27 Dec 2013

Adding drug to presurgery chemotherapy improves results for women with triple-negative breast cancer

The I-SPY 2 trial, an innovative, multidrug, phase II breast cancer trial, has yielded positive results with the first drug to complete testing in the trial. Adding the chemotherapy carboplatin and the molecularly targeted drug veliparib to standard presurgery chemotherapy improved outcomes for women with triple-negative breast cancer, according to results from the I-SPY 2 trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

16 Dec 2013

Researchers test promising new breast cancer drugs

The first investigator results from an unprecedented nationwide effort to test promising new breast cancer drugs before the tumor is removed were presented during the 2013 San Antonio Breast Cancer Symposium.

14 Dec 2013